Blog
“Each patient’s care plan is personalized and tailored to their specific cancer,” she said. “Genomics now plays a huge role—helping guide decisions not only for chemotherapy, from a systemic standpoint, but also for radiation.”
“Every DCIS patient deserves access to this kind of personalized information. I’m grateful I had the chance to use DCISionRT—and I’m committed to ensuring others know it’s available to them, too.”
“Patients can see specific percentages for DCIS recurrence, invasive cancer recurrence or a combination of both,” Dr. Williams says. “These details empower patients to make informed decisions about their treatment.”
“My DCISionRT results showed me that my treatment could be complete after surgery. I felt like I won the lottery!”
“When you hear the word ‘cancer,’ that’s scary,” LeeAnne says. “But once you realize these are the cards you’re dealt, you have to accept it and take it head-on.”
I was diagnosed with DCIS in 2019 at age 41 and chose a lumpectomy followed by radiation. With the information I had during my decision-making process, radiation made sense. At the time, I didn’t know about DCISionRT.
“I find that the DCISionRT test has significantly changed how we approach radiation therapy recommendations. I've been ordering the DCISionRT test on the majority of my patients over the last couple of years.”
“I am 100% sure that had I not been diagnosed with breast cancer I would not be doing this work. Working in a company like PreludeDx on the diagnostic side, I’m able to touch far more lives than I could if I was still in practice as a Physician Associate. I can get in front of 30 – 40 physicians over 6 months and help hundreds of women with decisions regarding their cancer diagnosis. I feel like I’m still involved in patient care. I just get to do it on a broader level where I’m impacting providers with a fundamental practice changing technology. PreludeDx is changing the status quo and making sure that these women have the information that they need.”
“I was an early adopter of DCISionRT and have been recommending it ever since the data was available. I order DCISionRT on every single one of my ductal carcinoma in situ (DCIS) patients. The DCISionRT test can change a lot of the discussions with colleagues and patients, as well as recommended treatments for DCIS.”
In this webinar, Eric Brown, MD, FACS; Erica Giblin, MD; James V. Pellicane, MD; Troy Bremer, PhD; and Leona Hamrick, DHSc, PA-C, MSL-BC, discuss how DCISionRT and its newly integrated Residual Risk Subtype (RRt) played a significant role in treatment decision making in DCIS patients identified in the RRt category. These key opinion leaders discuss actual patient cases with RRt, the differentiating factors among cases, patient preference and final treatment decisions.
